Day One Biopharmaceuticals (DAWN) Projected to Post Earnings on Tuesday

Day One Biopharmaceuticals (NASDAQ:DAWN) will likely be announcing its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

Day One Biopharmaceuticals Trading Up 3.2%

Day One Biopharmaceuticals stock opened at $11.35 on Tuesday. The stock has a 50-day moving average price of $10.21 and a 200 day moving average price of $8.51. Day One Biopharmaceuticals has a 52 week low of $5.64 and a 52 week high of $13.20. The stock has a market cap of $1.17 billion, a PE ratio of -7.47 and a beta of -1.26.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Brevan Howard Capital Management LP purchased a new position in shares of Day One Biopharmaceuticals in the 3rd quarter valued at $171,000. Creative Planning raised its position in Day One Biopharmaceuticals by 41.5% in the third quarter. Creative Planning now owns 26,196 shares of the company’s stock valued at $185,000 after purchasing an additional 7,689 shares during the period. Magnetar Financial LLC purchased a new position in Day One Biopharmaceuticals in the third quarter valued at about $116,000. Bayesian Capital Management LP lifted its stake in shares of Day One Biopharmaceuticals by 56.1% during the second quarter. Bayesian Capital Management LP now owns 28,100 shares of the company’s stock worth $183,000 after purchasing an additional 10,100 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Day One Biopharmaceuticals in the second quarter worth about $158,000. Institutional investors and hedge funds own 87.95% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. TD Cowen began coverage on shares of Day One Biopharmaceuticals in a research report on Tuesday, January 13th. They issued a “buy” rating and a $34.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 target price on shares of Day One Biopharmaceuticals in a research note on Monday, November 24th. Zacks Research raised Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 26th. JPMorgan Chase & Co. raised their price objective on Day One Biopharmaceuticals from $26.00 to $27.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of Day One Biopharmaceuticals in a research note on Monday, November 24th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $25.71.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.